Saffron as a Promising Therapy for Inflammatory Bowel Disease

被引:1
|
作者
Rashid, Mudasir [1 ,2 ]
Rashid, Rumaisa [1 ,2 ]
Saroya, Sabtain [1 ,2 ]
Deverapalli, Mrinalini [1 ,2 ]
Brim, Hassan [1 ,2 ]
Ashktorab, Hassan [1 ,2 ]
机构
[1] Howard Univ, Coll Med, Dept Med, Washington, DC 20059 USA
[2] Howard Univ, Coll Med, Canc Ctr, Washington, DC 20059 USA
基金
美国国家卫生研究院;
关键词
IBD; CD; UC; calprotectin; saffron; CROCUS-SATIVUS-L; TO-MODERATE DEPRESSION; INDUCED OXIDATIVE STRESS; DOUBLE-BLIND; ULCERATIVE-COLITIS; COLORECTAL-CANCER; IN-VITRO; NEUTROPHILIC INFLAMMATION; IMMUNOSUPPRESSIVE THERAPY; ALZHEIMERS-DISEASE;
D O I
10.3390/nu16142353
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Inflammatory bowel disease (IBD) is a chronic inflammatory illness of the gastrointestinal tract (GI), characterized by recurrent episodes of inflammation and tissue destruction. It affects an increasing number of individuals worldwide who suffer from Crohn's disease (CD) or ulcerative colitis (UC). Despite substantial advances in understanding the underlying causes of IBD, the available treatments remain restricted and are sometimes accompanied by severe consequences. Consequently, there is an urgent need to study alternate therapeutic options. This review assesses the present drugs, identifies their limitations, and proposes the use of saffron, a natural plant with great therapeutic potential based on preclinical and clinical investigations. Saffron has gained attention for its potential therapeutic benefits in treating various ailments due to its established bioactive compounds possessing antioxidant and anti-inflammatory properties. This review covers how saffron impacts the levels of calprotectin, an inflammatory marker, for various inflammatory responses in multiple diseases including IBD. Data from clinical trials were assessed to determine the efficacy and safety of using saffron to counter inflammation in multiple diseases. Studies have shown that saffron may protect against inflammatory bowel disease (IBD) through several mechanisms by inhibiting pro-inflammatory cytokines (TNF-alpha, IL-1 beta, and IL-6), reducing oxidative stress through antioxidant effects, enhancing mucosal barrier function by upregulating tight junction proteins, and modulating the gut microbiota composition to promote beneficial bacteria while suppressing pathogenic ones; these combined actions contribute to its therapeutic potential in managing and alleviating the symptoms of IBD. This will enable future research endeavors and expedite the translation of saffron-based interventions into clinical practice as a valuable adjunctive therapy or a potential alternative to conventional treatments, thereby enhancing the quality of life for individuals suffering from inflammatory diseases including IBD.
引用
收藏
页数:24
相关论文
共 50 条
  • [41] Immunomodulatory therapy for inflammatory bowel disease
    Kusugami, K
    Ina, K
    Ando, T
    Hibi, K
    Nishio, Y
    Goto, H
    JOURNAL OF GASTROENTEROLOGY, 2004, 39 (12) : 1129 - 1137
  • [42] Local therapy for inflammatory bowel disease
    Melanie Brazil
    Nature Reviews Drug Discovery, 2005, 4 : 958 - 958
  • [43] Drug therapy of inflammatory bowel disease
    Egan, LJ
    Sandborn, WJ
    DRUGS OF TODAY, 1998, 34 (05): : 431 - 446
  • [44] Maintenance therapy for inflammatory bowel disease
    Feagan, BG
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (12): : S6 - S17
  • [45] Alicaforsen therapy in inflammatory bowel disease
    Barish, CF
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2005, 5 (10) : 1387 - 1391
  • [46] Combination therapy for inflammatory bowel disease
    Keith S Sultan
    Joshua C Berkowitz
    Sundas Khan
    World Journal of Gastrointestinal Pharmacology and Therapeutics, 2017, (02) : 103 - 113
  • [47] Thiopurine therapy in inflammatory bowel disease
    Ha, Christina
    Dassopoulos, Themistocles
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 4 (05) : 575 - 588
  • [48] Personalised therapy for inflammatory bowel disease
    Ashton, James J.
    Beattie, R. Mark
    LANCET, 2019, 393 (10182): : 1672 - 1674
  • [49] The future of inflammatory bowel disease therapy
    van Deventer, SJH
    INFLAMMATORY BOWEL DISEASES, 2002, 8 (04) : 301 - 305
  • [50] Gene therapy for inflammatory bowel disease
    van Deventer, SJH
    IBD AND SALICYLATES - 5, 2001, 24 (01): : 87 - 92